IRLAB Therapeutics
14.85
SEK
+1.71 %
IRLAB A
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+1.71%
+24.79%
+38.14%
+5.32%
-11.87%
-17.04%
-60.13%
-46.6%
+28.07%
IRLAB Therapeutics is a Swedish research and pharmaceutical company. The research is based on the company's own research platform and specializes in the treatment of brain diseases, commonly referred to as neurodegenerative diseases. At the present, the company holds drug candidates specializing in, among other things, Parkinson's disease. The head office is located in Gothenburg.
Read moreMarket cap
770.25M SEK
Turnover
189.69K SEK
Revenue
5.68M
EBIT %
-3,182.57 %
P/E
-
Dividend yield-%
-
Financial calendar
12.2
2025
Annual report '24
7.5
2025
Interim report Q1'25
21.5
2025
General meeting '25
ShowingAll content types
IRLAB to Present at Redeye Investor Forum
IRLAB has received a waiver from the EMA regarding pediatric studies with mesdopetam in Parkinson's Disease
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools